NASDAQ:INCY
Incyte Corporation Stock News
$57.10
+0.240 (+0.422%)
At Close: May 17, 2024
10 Stocks To Buy With Low Debt And High Liquidity
08:15am, Friday, 27'th Mar 2020
Given the near-term economic uncertainty surrounding the COVID-19 outbreak, investors have been shifting their focus from growth stocks to stocks that have the balance sheets and liquidity to weather
Incyte (INCY) Down 5.4% Since Last Earnings Report: Can It Rebound?
11:30am, Saturday, 14'th Mar 2020
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating
03:12pm, Tuesday, 10'th Mar 2020
On Tuesday, Incyte got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.
The post Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on Investor's Busine
These 2 Things Will Help Incyte’s Stock Rebound
10:00am, Wednesday, 04'th Mar 2020
Here's why Incyte could recover from its poor performance in recent weeks.
Incyte A Buy On 2020 Guidance And Possible Drug Approvals
03:48pm, Wednesday, 19'th Feb 2020
Incyte A Buy On 2020 Guidance And Possible Drug Approvals
Incyte's Ruxolitinib Works in Patients With Eczema
12:37pm, Wednesday, 19'th Feb 2020
The biotech company just reported data from a pair of successful late-stage clinical trials.
Better Buy: Vertex Pharmaceuticals vs. Incyte
11:45am, Wednesday, 19'th Feb 2020
Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2019 Results - Earnings Call Transcript
02:27pm, Thursday, 13'th Feb 2020
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2019 Results - Earnings Call Transcript
How Incyte Beat Wall Street Estimates in Q4
12:00pm, Thursday, 13'th Feb 2020
The biotech posted strong sales growth for all three of its approved drugs.
Incyte's Fourth-Quarter Report Signals Better Times Ahead
11:18am, Thursday, 13'th Feb 2020
Though the pharmaceutical company reported a big clinical trial failure last month, there are other reasons for optimism.
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
10:24am, Thursday, 13'th Feb 2020
Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.
Incyte (INCY) Q4 Earnings and Revenues Beat Estimates
08:35am, Thursday, 13'th Feb 2020
Incyte (INCY) delivered earnings and revenue surprises of 12.07% and 1.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
06:32pm, Wednesday, 12'th Feb 2020
The drug moves closer to an expanded approval for the skin disorder.
Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA
10:45am, Tuesday, 11'th Feb 2020
The Food and Drug Administration will expedite its review of capmatinib.
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
09:04am, Tuesday, 11'th Feb 2020
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
